Neuroinflammation-the role of heteroreceptor complexes

Abstract

Neuroinflammation is a hallmark of various neurodegenerative and neuropsychiatric disorders, driven by complex interactions between neurotransmitter receptors and immune signaling pathways. Among these, heteroreceptor complexes-functional assemblies formed by the physical interaction of different G protein-coupled or ionotropic receptor subtypes within the same membrane microdomain-play a crucial role in modulating synaptic activity, neuroimmune responses, and inflammatory cascades. For example, the A2A-D2 receptor complex modulates dopaminergic signaling in the striatum and has been implicated in Parkinson’s disease pathology. These receptor-receptor interactions influence key signaling pathways involving dopamine, serotonin, glutamate, adenosine, and cannabinoid systems, thereby contributing to the pathophysiology of Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, schizophrenia, and depression. Dysregulation of heteroreceptor complexes disrupts neuronal homeostasis, exacerbates neuroinflammatory responses, and influences microglial and astrocytic activation. Understanding the molecular mechanisms governing these interactions, including allosteric modulation and biased agonism, offers novel therapeutic avenues for targeting neuroinflammation. Pharmacological strategies, such as selective allosteric modulators, biased agonists, and receptor-specific ligands, aim to restore heteroreceptor function and mitigate neuroinflammatory damage. Emerging clinical trials-such as those evaluating A2A receptor antagonists like istradefylline for Parkinson’s disease and 5-HT2A antagonists for schizophrenia-have shown promising neuroprotective and anti-inflammatory effects, although larger-scale, long-term studies are needed to confirm efficacy. This review highlights the pivotal role of heteroreceptor complexes in neuroinflammation, discusses their therapeutic potential, and underscores the need for further research into their functional dynamics to develop effective interventions for neurodegenerative and neuropsychiatric diseases.

Keywords

Astrocytic / inflammatory cascades / neurodegenerative / neuropsychiatric / microglial

References

[1] Kölliker-Frers R, Udovin L, Otero-Losada M, Kobiec T, Herrera MI, Palacios J, et al. Neuroinflammation: An Integrating Overview of Reactive-Neuroimmune Cell Interactions in Health and Disease. Mediators Inflamm. 2021; 2021: 9999146.

[2] Teleanu DM, Niculescu AG, Lungu II, Radu CI, Vladâcenco O, Roza E, et al. An Overview of Oxidative Stress, Neuroinflammation, and Neurodegenerative Diseases. Int J Mol Sci. 2022; 23: 5938.

[3] Hassamal S. Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories. Front Psychiatry. 2023; 14: 1130989.

[4] Valente M, Dentoni M, Bellizzi F, Kuris F, Gigli GL. Specialized Pro-Resolving Mediators in Neuroinflammation: Overview of Studies and Perspectives of Clinical Applications. Molecules. 2022; 27: 4836.

[5] Alsbrook DL, Di Napoli M, Bhatia K, Biller J, Andalib S, Hinduja A, et al. Neuroinflammation in Acute Ischemic and Hemorrhagic Stroke. Curr Neurol Neurosci Rep. 2023; 23: 407-31.

[6] Rivas-Santisteban R, Lillo J, Raïch I, Muñoz A, Lillo A, Rodríguez-Pérez AI, et al. The cannabinoid CB₁ receptor interacts with the angiotensin AT2 receptor. Overexpression of AT₂-CB₁ receptor heteromers in the striatum of 6-hydroxydopamine hemilesioned rats. Exp Neurol. 2023; 362: 114319.

[7] Kiran NS, Vaishnavi G, Lowkesh G, Yashaswini C, Rajagopal S. Immune System and Obsessive-Compulsive Disorder: Intervention Through Immunotherapy. In: Nutrition and Obsessive-Compulsive Disorder. London: CRC Press; 2023. pp. 236-51.

[8] Kiran NS, Yashaswini C, Lowkesh G, Range K, Madhu R. Phytochemicals and Herbal Medicines: Potential Drug Candidates for Obsessive-Compulsive Disorder Treatment. In: Nutrition and Obsessive-Compulsive Disorder. London: CRC Press; 2023. pp. 189-200.

[9] Akyuz E, Polat AK, Eroglu E, Kullu I, Angelopoulou E, Paudel YN. Revisiting the role of neurotransmitters in epilepsy: An updated review. Life Sci. 2021; 265: 118826.

[10] Zhang H, Wang Z, Wang G, Song X, Qian Y, Liao Z, et al. Understanding the Connection between Gut Homeostasis and Psychological Stress. J Nutr. 2023; 153: 924-39.

[11] Stolero N, Frenkel D. The dialog between neurons and microglia in Alzheimer’s disease: The neurotransmitters view. J Neurochem. 2021; 158: 1412-24.

[12] Nimgampalle M, Chakravarthy H, Sharma S, Shree S, Bhat AR, Pradeepkiran JA, et al. Neurotransmitter systems in the etiology of major neurological disorders: Emerging insights and therapeutic implications. Ageing Res Rev. 2023; 89: 101994.

[13] Ludhiadch A, Sharma R, Muriki A, Munshi A. Role of Calcium Homeostasis in Ischemic Stroke: A Review. CNS & Neurological Disorders-Drug Targets. 2022; 21: 52-61. [DOI]

[14] Abruzzo PM, Panisi C, Marini M. The Alteration of Chloride Homeostasis/GABAergic Signaling in Brain Disorders: Could Oxidative Stress Play a Role? Antioxidants (Basel). 2021; 10: 1316.

[15] Lim D, Jeong J, Song J. Lipocalin 2 regulates iron homeostasis, neuroinflammation, and insulin resistance in the brains of patients with dementia: Evidence from the current literature. CNS Neurosci Ther. 2021; 27: 883-94.

[16] Pérez de la Mora M, Borroto-Escuela DO, Crespo-Ramírez M, Rejón-Orantes JDC, Palacios-Lagunas DA, Martínez-Mata MK, et al. Dysfunctional Heteroreceptor Complexes as Novel Targets for the Treatment of Major Depressive and Anxiety Disorders. Cells. 2022; 11: 1826.

[17] Lillo A, Raïch I, Lillo J, Pérez-Olives C, Navarro G, Franco R. Expression of the Adenosine A_2A-A₃ Receptor Heteromer in Different Brain Regions and Marked Upregulation in the Microglia of the Transgenic APP_Sw,_Ind Alzheimer’s Disease Model. Biomedicines. 2022; 10: 214.

[18] Borroto-Escuela DO, Ambrogini P, Narvaez M, Di Liberto V, Beggiato S, Ferraro L, et al. Serotonin Heteroreceptor Complexes and Their Integration of Signals in Neurons and Astroglia-Relevance for Mental Diseases. Cells. 2021; 10: 1902.

[19] Rico AJ, Dopeso-Reyes IG, Martínez-Pinilla E, Sucunza D, Pignataro D, Roda E, et al. Neurochemical evidence supporting dopamine D1-D2 receptor heteromers in the striatum of the long-tailed macaque: changes following dopaminergic manipulation. Brain Struct Funct. 2017; 222: 1767-84.

[20] Narváez M, Crespo-Ramírez M, Fores-Pons R, Pita-Rodríguez M, Ciruela F, Filip M, et al. Study of GPCR Homo- and Heteroreceptor Complexes in Specific Neuronal Cell Populations Using the In Situ Proximity Ligation Assay. Receptor and Ion Channel Detection in the Brain. 2021: 117-34. [DOI]

[21] ElNebrisi E, Lozon Y, Oz M. The Role of α7-Nicotinic Acetylcholine Receptors in the Pathophysiology and Treatment of Parkinson’s Disease. Int J Mol Sci. 2025; 26: 3210.

[22] Arrabal-Gómez C, Beltran-Casanueva R, Hernández-García A, Bayolo-Guanche JV, Barbancho-Fernández MA, Serrano-Castro PJ, et al. Enhancing Cognitive Functions and Neuronal Growth through NPY1R Agonist and Ketamine Co-Administration: Evidence for NPY1R-TrkB Heteroreceptor Complexes in Rats. Cells. 2024; 13: 669.

[23] Pinna A, Bonaventura J, Farré D, Sánchez M, Simola N, Mallol J, et al. _L-DOPA disrupts adenosine A_2A-cannabinoid CB₁-dopamine D₂ receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: Biochemical and behavioral studies. Exp Neurol. 2014; 253: 180-91.

[24] Ilchibaeva T, Tsybko A, Zeug A, Müller FE, Guseva D, Bischoff S, et al. Serotonin Receptor 5-HT_2A Regulates TrkB Receptor Function in Heteroreceptor Complexes. Cells. 2022; 11: 2384.

[25] Borroto-Escuela DO, Ferraro L, Beggiato S, Narváez M, Fores-Pons R, Alvarez-Contino JE, et al. The coming together of allosteric and phosphorylation mechanisms in the molecular integration of A2A heteroreceptor complexes in the dorsal and ventral striatal-pallidal GABA neurons. Pharmacol Rep. 2021; 73: 1096-108.

[26] Ren P, Wang JY, Xu MJ, Chen HL, Duan JY, Li YF. Sigma-1 receptor activation produces faster antidepressant-like effect through enhancement of hippocampal neuroplasticity: Focus on sigma-1-5-HT1A heteroreceptor complex. Neurochemistry International. 2025; 184: 105937.

[27] Ambrogini P, Lattanzi D, Pagliarini M, Di Palma M, Sartini S, Cuppini R, et al. 5HT1AR-FGFR1 Heteroreceptor Complexes Differently Modulate GIRK Currents in the Dorsal Hippocampus and the Dorsal Raphe Serotonin Nucleus of Control Rats and of a Genetic Rat Model of Depression. Int J Mol Sci. 2023; 24: 7467.

[28] Martínez-Pinilla E, Rico AJ, Rivas-Santisteban R, Lillo J, Roda E, Navarro G, et al. Expression of GPR55 and either cannabinoid CB₁ or CB₂ heteroreceptor complexes in the caudate, putamen, and accumbens nuclei of control, parkinsonian, and dyskinetic non-human primates. Brain Struct Funct. 2020; 225: 2153-64.

[29] Bonaventura J, Rico AJ, Moreno E, Sierra S, Sánchez M, Luquin N, et al. _L-DOPA-treatment in primates disrupts the expression of A_2A adenosine-CB₁ cannabinoid-D₂ dopamine receptor heteromers in the caudate nucleus. Neuropharmacology. 2014; 79: 90-100.

[30] Guidolin D, Tortorella C, Marcoli M, Cervetto C, De Caro R, Maura G, et al. Possible roles of heteroreceptor complexes in excitotoxic processes. Explor Neuroprot Ther. 2024; 4: 366-91. [DOI]

[31] Yan Q, Li XJ, Wang QQ, Jia W, Wang SL. FGF21 Exhibits Neuroprotective Effects by Promoting 5-HT_1AR-FGFR1 Heteroreceptor Complexes and Triggering MEK_1/2-ERK_1/2 Signaling Pathway. Mol Neurobiol. 2025; 62: 6369-82.

[32] Mirchandani-Duque M, Choucri M, Hernández-Mondragón JC, Crespo-Ramírez M, Pérez-Olives C, Ferraro L, et al. Membrane Heteroreceptor Complexes as Second-Order Protein Modulators: A Novel Integrative Mechanism through Allosteric Receptor-Receptor Interactions. Membranes (Basel). 2024; 14: 96.

[33] Fuxe K, Guidolin D, Agnati LF, Borroto-Escuela DO. Dopamine heteroreceptor complexes as therapeutic targets in Parkinson’s disease. Expert Opin Ther Targets. 2015; 19: 377-98.

[34] Borroto-Escuela DO, Cuesta-Marti C, Lopez-Salas A, Chruścicka-Smaga B, Crespo-Ramírez M, Tesoro-Cruz E, et al. The oxytocin receptor represents a key hub in the GPCR heteroreceptor network: potential relevance for brain and behavior. Front Mol Neurosci. 2022; 15: 1055344.

[35] Borroto-Escuela DO, Fuxe K. Adenosine heteroreceptor complexes in the basal ganglia are implicated in Parkinson’s disease and its treatment. J Neural Transm (Vienna). 2019; 126: 455-71.

[36] Porzionato A, Stocco E, Guidolin D, Agnati L, Macchi V, De Caro R. Receptor-Receptor Interactions of G Protein-Coupled Receptors in the Carotid Body: A Working Hypothesis. Front Physiol. 2018; 9: 697.

[37] Borroto-Escuela DO, Wydra K, Filip M, Fuxe K. A2AR-D2R Heteroreceptor Complexes in Cocaine Reward and Addiction. Trends Pharmacol Sci. 2018; 39: 1008-20.

[38] Borroto-Escuela DO, Romero-Fernandez W, Garriga P, Ciruela F, Narvaez M, Tarakanov AO, et al. G protein-coupled receptor heterodimerization in the brain. Methods Enzymol. 2013; 521: 281-94.

[39] Rodríguez-Ruiz M, Moreno E, Moreno-Delgado D, Navarro G, Mallol J, Cortés A, et al. Heteroreceptor Complexes Formed by Dopamine D₁, Histamine H₃, and N-Methyl-D-Aspartate Glutamate Receptors as Targets to Prevent Neuronal Death in Alzheimer’s Disease. Mol Neurobiol. 2017; 54: 4537-50.

[40] Feltmann K, Borroto-Escuela DO, Rüegg J, Pinton L, de Oliveira Sergio T, Narváez M, et al. Effects of Long-Term Alcohol Drinking on the Dopamine D2 Receptor: Gene Expression and Heteroreceptor Complexes in the Striatum in Rats. Alcohol Clin Exp Res. 2018; 42: 338-51.

[41] Di Liberto V, Borroto-Escuela DO, Frinchi M, Verdi V, Fuxe K, Belluardo N, et al. Existence of muscarinic acetylcholine receptor (mAChR) and fibroblast growth factor receptor (FGFR) heteroreceptor complexes and their enhancement of neurite outgrowth in neural hippocampal cultures. Biochim Biophys Acta Gen Subj. 2017; 1861: 235-45.

[42] Narváez M, Andrade-Talavera Y, Valladolid-Acebes I, Fredriksson M, Siegele P, Hernandez-Sosa A, et al. Existence of FGFR1-5-HT1AR heteroreceptor complexes in hippocampal astrocytes. Putative link to 5-HT and FGF2 modulation of hippocampal gamma oscillations. Neuropharmacology. 2020; 170: 108070.

[43] Lamirande Ed, Gagnon C. The extracellular signal-regulated kinase (ERK) pathway is involved in human sperm function and modulated by the superoxide anion. Mol Hum Reprod. 2002; 8: 124-35.

[44] Frankland PW, Josselyn SA. Hippocampal Neurogenesis and Memory Clearance. Neuropsychopharmacology. 2016; 41: 382-3.

[45] Morén C, deSouza RM, Giraldo DM, Uff C. Antioxidant Therapeutic Strategies in Neurodegenerative Diseases. Int J Mol Sci. 2022; 23: 9328.

[46] Kumari R, Shekhar N, Tyagi S, Thakur AK. Mitochondrial dysfunctions and neurodegenerative diseases: A mini-review. J Anal Pharm Res. 2021; 10: 147-9. [DOI]

[47] Garcia-Garcia AL, Newman-Tancredi A, Leonardo ED. P5-HT_1A receptors in mood and anxiety: recent insights into autoreceptor versus heteroreceptor function. Psychopharmacology (Berl). 2014; 231: 623-36.

[48] Batistič O, Kudla J. Analysis of calcium signaling pathways in plants. Biochimica et Biophysica Acta (BBA)-General Subjects. 2012; 1820: 1283-93. [DOI]

[49] Buck SA, Erickson-Oberg M, Logan RW, Freyberg Z. Relevance of interactions between dopamine and glutamate neurotransmission in schizophrenia. Mol Psychiatry. 2022; 27: 3583-91.

[50] Fedotova EI, Abramov AY, Berezhnov AV. Dopamine Protects Neurons against Glutamate-Induced Excitotoxicity. Biochem. 2023; 17: 34-42. [DOI]

[51] Solís O, Moratalla R. Dopamine receptors: homomeric and heteromeric complexes in L-DOPA-induced dyskinesia. J Neural Transm (Vienna). 2018; 125: 1187-94.

[52] Bloem BR, Okun MS, Klein C. Parkinson’s disease. Lancet. 2021; 397: 2284-303.

[53] Borroto-Escuela DO, Pintsuk J, Schäfer T, Friedland K, Ferraro L, Tanganelli S, et al. Multiple D2 heteroreceptor complexes: new targets for treatment of schizophrenia. Ther Adv Psychopharmacol. 2016; 6: 77-94.

[54] Navarro G, Borroto-Escuela D, Angelats E, Etayo Í, Reyes-Resina I, Pulido-Salgado M, et al. Receptor-heteromer mediated regulation of endocannabinoid signaling in activated microglia. Role of CB₁ and CB₂ receptors and relevance for Alzheimer’s disease and levodopa-induced dyskinesia. Brain, behavior, and immunity. 2018; 67: 139-51. [DOI]

[55] Ferré S, Agnati LF, Ciruela F, Lluis C, Woods AS, Fuxe K, et al. Neurotransmitter receptor heteromers and their integrative role in ‘local modules’: The striatal spine module. Brain Res Rev. 2007; 55: 55-67.

[56] Hoque KE, Indorkar RP, Sammut S, West AR. Impact of dopamine-glutamate interactions on striatal neuronal nitric oxide synthase activity. Psychopharmacology (Berl). 2010; 207: 571-81.

[57] Trejo-Lopez JA, Yachnis AT, Prokop S. Neuropathology of Alzheimer’s Disease. Neurotherapeutics. 2022; 19: 173-85.

[58] Liu TW, Chen CM, Chang KH. Biomarker of Neuroinflammation in Parkinson’s Disease. Int J Mol Sci. 2022; 23: 4148.

[59] Araújo B, Caridade-Silva R, Soares-Guedes C, Martins-Macedo J, Gomes ED, Monteiro S, et al. Neuroinflammation and Parkinson’s Disease-From Neurodegeneration to Therapeutic Opportunities. Cells. 2022; 11: 2908.

[60] Badanjak K, Fixemer S, Smajić S, Skupin A, Grünewald A. The Contribution of Microglia to Neuroinflammation in Parkinson’s Disease. Int J Mol Sci. 2021; 22: 4676.

[61] Grotemeyer A, McFleder RL, Wu J, Wischhusen J, Ip CW. Neuroinflammation in Parkinson's Disease - Putative Pathomechanisms and Targets for Disease-Modification. Front Immunol. 2022; 13: 878771.

[62] Nociti V, Romozzi M. The Role of BDNF in Multiple Sclerosis Neuroinflammation. Int J Mol Sci. 2023; 24: 8447.

[63] Azzolini F, Gilio L, Pavone L, Iezzi E, Dolcetti E, Bruno A, et al. Neuroinflammation Is Associated with GFAP and sTREM2 Levels in Multiple Sclerosis. Biomolecules. 2022; 12: 222.

[64] Al-Badri G, Castorina A. Insights into the Role of Neuroinflammation in the Pathogenesis of Multiple Sclerosis. J Funct Morphol Kinesiol. 2018; 3: 13.

[65] Colasanti A, Guo Q, Giannetti P, Wall MB, Newbould RD, Bishop C, et al. Hippocampal Neuroinflammation, Functional Connectivity, and Depressive Symptoms in Multiple Sclerosis. Biol Psychiatry. 2016; 80: 62-72.

[66] Feng T, Tripathi A, Pillai A. Inflammatory Pathways in Psychiatric Disorders: The case of Schizophrenia and Depression. Curr Behav Neurosci Rep. 2020; 7: 128-38.

[67] Maier R, Moser G, Chen GB, Ripke S, Coryell W, Potash JB, et al.; Cross-Disorder Working Group of the Psychiatric Genomics Consortium. Joint Analysis of Psychiatric Disorders Increases Accuracy of Risk Prediction for Schizophrenia, Bipolar Disorder, and Major Depressive Disorder. Am J Hum Genet. 2015; 96: 283-94.

[68] Musella A, Gentile A, Rizzo FR, De Vito F, Fresegna D, Bullitta S, et al. Interplay Between Age and Neuroinflammation in Multiple Sclerosis: Effects on Motor and Cognitive Functions. Front Aging Neurosci. 2018; 10: 238.

[69] Baker D, Jackson SJ, Pryce G. Cannabinoid control of neuroinflammation related to multiple sclerosis. Br J Pharmacol. 2007; 152: 649-54.

[70] Gilsbach R, Hein L. Are the pharmacology and physiology of α₂ adrenoceptors determined by α₂-heteroreceptors and autoreceptors respectively? Br J Pharmacol. 2012; 165: 90-102.

[71] Wydra K, Gawliński D, Frankowska M, Gawlińska K, Borroto-Escuela DO, Fuxe K. Heteroreceptor Complexes in Substance Use Disorders. Handbook of Neurotoxicity. 2022: 1-29. [DOI]

[72] Morris G, Berk M, Galecki P, Walder K, Maes M. The Neuro-Immune Pathophysiology of Central and Peripheral Fatigue in Systemic Immune-Inflammatory and Neuro-Immune Diseases. Mol Neurobiol. 2016; 53: 1195-219.

[73] Talbot S, Foster SL, Woolf CJ. Neuroimmunity: Physiology and Pathology. Annu Rev Immunol. 2016; 34: 421-47.

[74] Choi YH, Laaker C, Hsu M, Cismaru P, Sandor M, Fabry Z. Molecular Mechanisms of Neuroimmune Crosstalk in the Pathogenesis of Stroke. Int J Mol Sci. 2021; 22: 9486.

[75] Chavan SS, Pavlov VA, Tracey KJ. Mechanisms and Therapeutic Relevance of Neuro-immune Communication. Immunity. 2017; 46: 927-42.

[76] Reemst K, Noctor SC, Lucassen PJ, Hol EM. The Indispensable Roles of Microglia and Astrocytes during Brain Development. Front Hum Neurosci. 2016; 10: 566.

[77] Kwon HS, Koh SH. Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Transl Neurodegener. 2020; 9: 42.

[78] Sen MK, Mahns DA, Coorssen JR, Shortland PJ. The roles of microglia and astrocytes in phagocytosis and myelination: Insights from the cuprizone model of multiple sclerosis. Glia. 2022; 70: 1215-50.

[79] Di Benedetto G, Burgaletto C, Bellanca CM, Munafò A, Bernardini R, Cantarella G. Role of Microglia and Astrocytes in Alzheimer’s Disease: From Neuroinflammation to Ca²⁺ Homeostasis Dysregulation. Cells. 2022; 11: 2728.

[80] Karve IP, Taylor JM, Crack PJ. The contribution of astrocytes and microglia to traumatic brain injury. Br J Pharmacol. 2016; 173: 692-702.

[81] Matejuk A, Ransohoff RM. Crosstalk Between Astrocytes and Microglia: An Overview. Front Immunol. 2020; 11: 1416.

[82] Kany S, Vollrath JT, Relja B. Cytokines in Inflammatory Disease. Int J Mol Sci. 2019; 20: 6008.

[83] Elsalhy M, Azizieh F, Raghupathy R. Cytokines as diagnostic markers of pulpal inflammation. Int Endod J. 2013; 46: 573-80.

[84] Ueland T, Gullestad L, Nymo SH, Yndestad A, Aukrust P, Askevold ET. Inflammatory cytokines as biomarkers in heart failure. Clin Chim Acta. 2015; 443: 71-7.

[85] Miliopoulos D, Gkouziouta A, Leontiadis E, Adamopoulos S. Cytokines and inflammatory markers. In: Oxford Textbook of Heart Failure. Oxford University Press; 2022. p. 193.

[86] Courtney JM, Ennis M, Elborn JS. Cytokines and inflammatory mediators in cystic fibrosis. J Cyst Fibros. 2004; 3: 223-31.

[87] Rabaan AA, Al-Ahmed SH, Muhammad J, Khan A, Sule AA, Tirupathi R, et al. Role of Inflammatory Cytokines in COVID-19 Patients: A Review on Molecular Mechanisms, Immune Functions, Immunopathology and Immunomodulatory Drugs to Counter Cytokine Storm. Vaccines (Basel). 2021; 9: 436.

[88] Liu C, Chu D, Kalantar-Zadeh K, George J, Young HA, Liu G. Cytokines: From Clinical Significance to Quantification. Adv Sci (Weinh). 2021; 8: e2004433.

[89] Dawidowski B, Górniak A, Podwalski P, Lebiecka Z, Misiak B, Samochowiec J. The Role of Cytokines in the Pathogenesis of Schizophrenia. J Clin Med. 2021; 10: 3849.

[90] Jagannath B, Lin KC, Pali M, Sankhala D, Muthukumar S, Prasad S. Temporal profiling of cytokines in passively expressed sweat for detection of infection using wearable device. Bioeng Transl Med. 2021; 6: e10220.

[91] Fontes-Cal TCM, Mattos RT, Medeiros NI, Pinto BF, Belchior-Bezerra M, Roque-Souza B, et al. Crosstalk Between Plasma Cytokines, Inflammation, and Liver Damage as a New Strategy to Monitoring NAFLD Progression. Front Immunol. 2021; 12: 708959.

[92] Bülow Anderberg S, Luther T, Berglund M, Larsson R, Rubertsson S, Lipcsey M, et al. Increased levels of plasma cytokines and correlations to organ failure and 30-day mortality in critically ill Covid-19 patients. Cytokine. 2021; 138: 155389.

[93] Slosky LM, Caron MG, Barak LS. Biased Allosteric Modulators: New Frontiers in GPCR Drug Discovery. Trends Pharmacol Sci. 2021; 42: 283-99.

[94] McNeill SM, Baltos JA, White PJ, May LT. Biased agonism at adenosine receptors. Cell Signal. 2021; 82: 109954.

[95] Kelly E, Conibear A, Henderson G. Biased Agonism: Lessons from Studies of Opioid Receptor Agonists. Annu Rev Pharmacol Toxicol. 2023; 63: 491-515.

[96] Ippolito M, Benovic JL. Biased agonism at β-adrenergic receptors. Cell Signal. 2021; 80: 109905.

[97] Eiger DS, Boldizsar N, Honeycutt CC, Gardner J, Rajagopal S. Biased agonism at chemokine receptors. Cell Signal. 2021; 78: 109862.

[98] Rong L, Li N, Zhang Z. Emerging therapies for glioblastoma: current state and future directions. J Exp Clin Cancer Res. 2022; 41: 142.

[99] Mishra-Kalyani PS, Amiri Kordestani L, Rivera DR, Singh H, Ibrahim A, DeClaro RA, et al. External control arms in oncology: current use and future directions. Ann Oncol. 2022; 33: 376-83.

[100] Smrke A, Anderson PM, Gulia A, Gennatas S, Huang PH, Jones RL. Future Directions in the Treatment of Osteosarcoma. Cells. 2021; 10: 172.

[101] Rivas-Santisteban R, Rico AJ, Muñoz A, Rodríguez-Pérez AI, Reyes-Resina I, Navarro G, et al. Boolean analysis shows a high proportion of dopamine D₂ receptors interacting with adenosine A_2A receptors in striatal medium spiny neurons of mouse and non-human primate models of Parkinson’s disease. Neurobiol Dis. 2023; 188: 106341.

[102] Eckerling A, Ricon-Becker I, Sorski L, Sandbank E, Ben-Eliyahu S. Stress and cancer: mechanisms, significance and future directions. Nat Rev Cancer. 2021; 21: 767-85.

[103] Li W, Wang F, Guo R, Bian Z, Song Y. Targeting macrophages in hematological malignancies: recent advances and future directions. J Hematol Oncol. 2022; 15: 110.

[104] Sadee W, Wang D, Hartmann K, Toland AE. Pharmacogenomics: Driving Personalized Medicine. Pharmacol Rev. 2023; 75: 789-814.

[105] Ingber DE. Human organs-on-chips for disease modelling, drug development and personalized medicine. Nat Rev Genet. 2022; 23: 467-91.

[106] Franco R, Navarro G, Martínez-Pinilla E. The adenosine A_2A receptor in the basal ganglia: Expression, heteromerization, functional selectivity and signalling. Int Rev Neurobiol. 2023; 170: 49-71.

[107] Feng Y, Lu Y. Immunomodulatory Effects of Dopamine in Inflammatory Diseases. Front Immunol. 2021; 12: 663102.

[108] Margoni M, Preziosa P, Rocca MA, Filippi M. Depressive symptoms, anxiety and cognitive impairment: emerging evidence in multiple sclerosis. Transl Psychiatry. 2023; 13: 264.

[109] Zahra A, Wang YF, Wang Q, Wu J. Shared Etiology in Autism Spectrum Disorder and Epilepsy with Functional Disability. Behav Neurol. 2022; 2022: 5893519.

[110] Correia AS, Cardoso A, Vale N. Highlighting Immune System and Stress in Major Depressive Disorder, Parkinson’s, and Alzheimer’s Diseases, with a Connection with Serotonin. Int J Mol Sci. 2021; 22: 8525.

[111] Pathak N, Vimal SK, Tandon I, Agrawal L, Hongyi C, Bhattacharyya S. Neurodegenerative Disorders of Alzheimer, Parkinsonism, Amyotrophic Lateral Sclerosis and Multiple Sclerosis: An Early Diagnostic Approach for Precision Treatment. Metab Brain Dis. 2022; 37: 67-104.

[112] Kuusimäki T, Al-Abdulrasul H, Kurki S, Hietala J, Hartikainen S, Koponen M, et al. Increased Risk of Parkinson’s Disease in Patients With Schizophrenia Spectrum Disorders. Mov Disord. 2021; 36: 1353-61.

[113] Thompson LJ, Genovese J, Hong Z, Singh MV, Singh VB. HIV-Associated Neurocognitive Disorder: A Look into Cellular and Molecular Pathology. Int J Mol Sci. 2024; 25: 4697.

[114] Kim K, Kim S, Myung W, Shim I, Lee H, Kim B, et al. Shared Genetic Background between Parkinson’s Disease and Schizophrenia: A Two-Sample Mendelian Randomization Study. Brain Sci. 2021; 11: 1042.